Department of Clinical Immunology, Henri Mondor Hospital, Université Paris XII Creteil, Creteil, France.
AIDS. 2010 Aug 24;24(13):2130-3. doi: 10.1097/QAD.0b013e32833c9353.
We report the concentrations of maraviroc in the cerebrospinal fluid (CSF) and plasma of six HIV-1-infected patients with both neurological impairment and detectable HIV-1 replication in CSF. One month after starting maraviroc, the viral load in the CSF decreased significantly (P = 0.005). The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC90) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173).
我们报告了 6 例 HIV-1 感染伴神经功能障碍和脑脊液中可检测到 HIV-1 复制的患者的马拉维若浓度，这 6 例患者的脑脊液和血浆浓度。在开始使用马拉维若治疗 1 个月后，脑脊液中的病毒载量显著下降（P = 0.005）。血浆中（中位数（范围）马拉维若浓度为 347ng/ml（123-2678）。4 例患者的脑脊液浓度高于 0.57ng/ml（0.06-10.7）的蛋白校正抑制浓度（IC90），中位数为 102ng/ml（35-173）。
